Janus Henderson Group
MLYS icon

Janus Henderson Group’s Mineralys Therapeutics MLYS Stock Holding History

Janus Henderson Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$537K Sell
19,848
-1,193,417
-98% -$35M ﹤0.01% 1977
2025
Q4 		$44M Buy
1,213,265
+1,193,417
+6,013% +$47.9M 0.02% 439
2025
Q3 		$753K Buy
19,848
+8,248
+71% +$178K ﹤0.01% 1804
2025
Q2 		$157K Buy
+11,600
New +$168K ﹤0.01% 2364
2023
Q4 		– Sell
-665,717
Closed -$6.34M – 2585
2023
Q3 		$6.34M Buy
665,717
+257,755
+63% +$3.36M ﹤0.01% 763
2023
Q2 		$6.97M Buy
407,962
+70,526
+21% +$1.05M ﹤0.01% 760
2023
Q1 		$5.27M Buy
+337,436
New +$5.68M ﹤0.01% 859

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Janus Henderson Group's MLYS Position: Q1 2026 in Review

Janus Henderson Group reduced its Mineralys Therapeutics (MLYS) stake by 98% in Q1 2026, selling an estimated $35M and leaving 19,848 shares worth $537K. The position accounts for ﹤0.01% of the portfolio, ranked #1977.

Janus Henderson Group first reported a position in MLYS in Q1 2023 and has held it in 7 quarters since. The position peaked at $44M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Janus Henderson Group held 19,848 shares of Mineralys Therapeutics worth $537K as of Q1 2026.
  • Janus Henderson Group sold 1,193,417 Mineralys Therapeutics shares in Q1 2026, an estimated $35M.
  • Mineralys Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1977 holding.
  • Janus Henderson Group first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • Janus Henderson Group's Mineralys Therapeutics position peaked at $44M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.